TN
TNMWF
TNL Mediagene
No data for this timeframe.
Vol
SEC Reports3
Recent Activity
May 12, 2026
SEC
TNL Mediagene disclosed receipt of a Nasdaq deficiency letter for failing to meet the minimum $2.5M stockholders' equity
6-K — Impact 8/10
May 12, 2026
SEC
TNL Mediagene filed its FY2025 annual report on Form 20-F, reporting a 7.2% YoY revenue decline to $45.0M (below its pre
6-K — Impact 8/10
Apr 30, 2026
SEC
TNL Mediagene's FY2025 20-F reveals a deeply distressed company: revenue declined 7.2% YoY to $45.0M, net loss was $44.6
20-F — Impact 8/10
Latest Reports
BEARISH
6-K
8/10
TNL Mediagene disclosed receipt of a Nasdaq deficiency letter for failing to meet the minimum $2.5M stockholders' equity
May 12, 2026
BEARISH
6-K
8/10
TNL Mediagene filed its FY2025 annual report on Form 20-F, reporting a 7.2% YoY revenue decline to $45.0M (below its pre
May 12, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 0 neutral. Avg impact: 8.0/10.
BEARISH
6-K
8/10
TNL Mediagene disclosed receipt of a Nasdaq deficiency letter for failing to meet the minimum $2.5M
May 12, 2026
BEARISH
6-K
8/10
TNL Mediagene filed its FY2025 annual report on Form 20-F, reporting a 7.2% YoY revenue decline to $
May 12, 2026
BEARISH
20-F
8/10
TNL Mediagene's FY2025 20-F reveals a deeply distressed company: revenue declined 7.2% YoY to $45.0M
Apr 30, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 12.3% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 7.7% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.